Elligo Health Research and Saama Technologies Announce Strategic Partnership to Advance Clinical Research Data Management
Austin, Texas, and Campbell, Calif., Feb. 28, 2018 (Business Wire)-Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, is partnering with Saama Technologies, Inc., a leading clinical data analytics company, to improve awareness of, access to, and participation in clinical trials for U.S. physicians and patients.
“We are excited to work with Saama to develop an innovative technology platform to transform the clinical research process overall, from standards-based data collection to eSubmissions to regulatory agencies,” said John Potthoff, Ph.D., Elligo CEO.
Through its Goes DirectTM model, Elligo engages physicians and their patients by first identifying patients using electronic health records and then providing their physicians with the infrastructure to conduct the research in their own offices at no cost to them. Saama’s award- winning Life Science Analytics Cloud, powered by its unique, AI-enabled Fluid Analytics Engine, includes the Cohort Builder and Trial Planning Optimizer solutions, which facilitate the identification of patient populations based on clinical trial eligibility requirements.
“Saama and Elligo have each pioneered innovative solutions that positively disrupt and improve the clinical trial landscape,” said Suresh Katta, founder and CEO of Saama. “Together, Saama and Elligo will set a new bar for physician and patient access to, and engagement with, clinical research that may improve patients’ health, enhance physicians’ understanding of disease management, and expand medical knowledge for treating some of the most prevalent and devastating human diseases.”
The partnership will help resolve the challenges sponsors face when they must assemble vast amounts of data from disparate sources.
“Saama’s groundbreaking analytics can deliver aggregated operational and clinical data to provide a multidimensional and real-time view of even multi-site trials,” Katta said. “By combining our life sciences solutions with Elligo’s unique approach and clinical research experience, we can improve data management to support accelerated research and development of meaningful therapeutics.”
“With Saama as a partner, Elligo will continue to improve access to standards-based eSource data directly from clinical research sites,” Potthoff added.
Meet with Saama and Elligo at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative, April 4–5 in National Harbor, Md.
About Elligo
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes DirectTM with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.
About Saama
Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. Saama is singularly focused on driving fast, flexible, impactful business outcomes for clients through data and analytics. Saama’s unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and big data technologies. Saama integrates manual and disconnected initiatives into a well-aligned roadmap, facilitating the client’s journey from strategy through solution implementation.
CONTACTS:
Lea Studer
Elligo Health Research
402.366.1752
lea@scorrmarketing.com
Crystal Black
Saama Technologies
408.371.1900
crystal.black@saama.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
